Mengxin Tech Unveils Medical-Grade Smart Watch After Eight Years of R&D, Empowering Primary Care with 96% ECG and 94% Blood Pressure Accuracy

“Practical data shows that the Mengxin Intelligent Remote Monitor achieves high accuracy in continuous monitoring of heart rate and electrocardiogram (ECG) data, reaching96%, blood pressure data accuracy reaches94%, the integrity of the ECG waveform can reach98%The aforementioned data not only surpasses the market average for smart health products but also meets medical-grade monitoring standards. With patient consent, primary care general practitioners can access user data via the physician interface of the cloud-based health management platform, thereby enabling tailored management of patients with chronic diseases.Zhao Xudong, Deputy General Manager of Operations at Zhuhai Mengxin Technology, confidently highlighted the advantages of his company’s testing terminals in an interview with VCBeat.

In January 2017, the State Council officially issued the “13th Five-Year Plan for Deepening the Reform of the Medical and Healthcare System,” in which tiered diagnosis and treatment remained the top priority of systemic reform. The Guiding Opinions on the Development of the Tiered Diagnosis and Treatment System clearly stipulated that “by 2017, pilot regions for tiered diagnosis and treatment should achieve several work standards: the compliance rate for the development of primary medical and healthcare institutions shall be ≥95%, and the proportion of consultations at primary medical and healthcare institutions to the total number of consultations shall be ≥65%.”

Primary healthcare is facing unprecedented development opportunities, but the shortage of general practitioners at the grassroots level is a prominent issue; therefore, improving the work efficiency of grassroots general practitioners is crucial.The Mengxin Intelligent Remote Monitoring and Health Management System is designed not only to acquire medical-grade monitoring data but also to empower primary care general practitioners in better managing patients, improving work efficiency, and thereby enabling them to serve a larger patient population.

Mengxin Technology has been dedicated to research and development in the field of personal intelligent remote vital signs monitoring and health management for eight years, developing the mostNew Third-Generation Intelligent Remote MonitorFeatures “pulse monitoring, blood pressure detection, ECG detection, global positioning,” and other auxiliary functions.while also integrating with the Qili Health Management Cloud Platform, enabling primary care physicians to access continuous medical-grade health data from patients in real time via PC platforms or mobile apps, and to conduct online consultations.

In terms of data collection, Mengxin Technology uses intelligent remote monitors as user vital sign monitoring and data collection terminals, connecting to the Qili Health Management Cloud Platform via a proprietary data link to establish personal health records for users and provide health management services. The terminals adopt GSM/CDMA communication methods, enabling 24/7 real-time reading and storage of users' vital sign data such as blood pressure, electrocardiogram (ECG), heart rate, and pulse.

Unlike the vast majority of wearable devices on the market, the Mengxin Intelligent Remote Monitor employs the "ECG signal method" for heart rate monitoring, which is currently the most commonly used and precise method for heart rate measurement at the professional medical grade. For pulse detection, it utilizes a self-developed, high anti-interference pulse detector that has achieved four major breakthroughs in biosensor technology and has been granted a national patent certificate.

In terms of data applications, patients and primary care physicians can access this data and the continuous data from health records at any time through the monitor display screen, PC platform interface, and APP interface. Primary care physicians can refer to continuous data such as blood pressure, electrocardiogram (ECG), and heart rate to conduct consultations, perform data analysis, and assist in diagnosis.It provides a more comprehensive assessment compared to the single-point, one-time tests performed by traditional ECG monitoring devices.

Additionally, this system can also be applied to chronic disease management.Recently, the General Office of the State Council officially issued the "Medium- and Long-Term Plan for Chronic Disease Prevention and Control in China (2017–2025)," deploying chronic disease prevention and control efforts for the next 5 to 10 years. The plan establishes "reducing premature mortality from major chronic diseases" as its core objective. The importance of preventing and controlling chronic diseases, particularly cardiovascular and cerebrovascular diseases, needs no further elaboration here.

Effective prevention of chronic diseases first requires real-time data monitoring, thereby enabling the strategy of “preventing disease before it occurs and preventing chronic conditions” with the support of primary care physicians.. As mentioned above, Mengxin Technology has achieved medical-grade monitoring, marking the successful completion of this first step.

Next, through Mengxin Technology’s Qili Health Management Cloud Platform, primary care physicians, primary healthcare institutions, and family contract doctors can access patient health data shared with authorization, enabling them toCategory Management, promptly identify abnormalities and provide diagnostic and treatment recommendations; it also offers services such as personal physician care, remote consultations, clinical application support, access to the latest medical information, and expert lecture training.

On Mengxin Technology’s Eight-Year Commitment to Focused R&DWhen asked why the company did not design and launch a transitional product to support its early market entry and profitability, Zhao Xudong candidly replied, “We did consider launching an initial transitional product. However, the core management team ultimately reached a consensus that health management is an industry that intersects with human life. Mengxin cannot abandon its corporate vision of building a world-class health management platform due to the short-sighted pursuit of rapid profitability. We have remained steadfast in our commitment, and now we are finally witnessing the dawn of the vast health industry.”

During the product research and development process over the past few years,Mengxin Technology has continued to collaborate with community health institutions across multiple communities in various cities, providing free medical examinations and testing experiences to nearly 10,000 individuals suffering from chronic diseases such as cardiovascular and cerebrovascular conditions, with a particular focus on middle-aged and elderly patients. This initiative aims to thoroughly gather feedback from grassroots healthcare workers and chronic disease patients regarding their experiences with the products and their needs for health management., and continuously refine our product design and cloud computing capabilities based on feedback.

Practical data shows that the Mengxin Intelligent Remote Monitor achieves 96% accuracy in heart rate and electrocardiogram (ECG) measurements, surpassing ordinary smartwatches and smart bands using photoplethysmography (PPG) by 6 percentage points. Its blood pressure measurement accuracy reaches 94%, fully outperforming traditional electronic sphygmomanometers. The completeness of ECG waveforms exceeds 98%, allowing clear and comprehensive interpretation of various ECG components, including P waves, Q waves, and T waves. All data can be independently operated by users at any time, automatically uploaded in real time, and shared upon authorization.

In addition to conducting tests among a broad user base, Mengxin Technology has invited Professor Hu Dayi, a renowned Chinese cardiovascular expert and Chairman of the China Heart Alliance, to serve as its Chief Medical Advisor, providing in-depth guidance on product implementation, health management architecture, and chronic disease prevention and control services.

Zhao Xudong revealed that, following nearly six months of continuous testing, validation, and data analysis, Mengxin’s products will be officially launched for sale in late March this year. The company expects to acquire 10 million users for remote monitoring and health management services within three years. In the future, Mengxin Technology aims to evolve into a diversified healthcare platform integrating health management, precision medicine, big data centers, and other services.